Vitamin D status and seroconversion for COVID-19 in UK healthcare workers. by Faniyi, Aduragbemi A et al.
Vitamin D status and seroconversion for
COVID-19 in UK healthcare workers
To the Editor:
The coronavirus disease 2019 (COVID-19) pandemic is a global health emergency, resulting in over 50
million infections and over 1.2 million deaths as of mid-November 2020 [1]. Healthcare workers are at a
high risk of COVID-19 with large numbers of deaths reported around Europe and the UK, particularly
among staff in the Black, Asian and minority ethnic (BAME) demographic group [2]. COVID-19 has
disproportionately affected BAME individuals even after accounting for age, sex, social deprivation and
comorbidity [3].
Vitamin D deficiency (VDD) is common in those of BAME ethnicity [4]. In VDD, both innate and
adaptive immunity becomes dysregulated, increasing the risk of respiratory infection, as seen in influenza,
common cold viruses and tuberculosis [5, 6]. There has been a great deal of interest in the role of VDD in
COVID-19, with recent evidence suggesting VDD is more frequent in patients with severe COVID-19
compared to mild cases [7]. The prevalence of VDD and association with COVID-19 in healthcare
workers has not been investigated.
We hypothesised that VDD was more common in healthcare workers who have seroconverted for
COVID-19. This study defined the factors associated with VDD and the relationship between COVID-19
seroconversion and VDD.
This cross-sectional observational study recruited healthcare workers between 12 and 22 May, 2020 from the
University Hospitals Birmingham NHS Foundation Trust (UHBFT) across four sites. This was a sub-study
of the COVID-19 convalescent immunity study (COCO) approved by the London – Camden and Kings
Cross Research Ethics Committee (20/HRA/1817). The main inclusion criteria were staff members who had
isolated for symptoms suggestive of COVID-19. After obtaining consent, blood samples were taken for
measurement of vitamin D levels by mass spectrometry, and anti-SARS-CoV-2 spike glycoprotein
antibodies using a combined IgG, IgA, IgM ELISA (The Binding Site; product code: MK654) [8]. This CE
marked assay has 98.6% (95% CI 92.6–100) sensitivity and 98.3% (95% CI 96.4–99.4) specificity. The
median time from symptom onset to sample collection was 48 days. COVID-19 seroconversion was used to
indicate previous infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). VDD was
defined as serum 25(OH)D3 concentration <30 nmol·L
−1 as per the UHBFT clinical laboratory reference
range and the UK National Osteoporosis Society guidance [9].
Of the 392 healthcare workers studied, 61 (15.6%) had VDD. The participant demographics, occupation
and seroconversion status are displayed in table 1. Those with VDD were significantly more likely to be
BAME (p<0.0001) and in a junior doctor job role (p=0.029); there were no differences in age, body mass
index or comorbidity status between those with VDD and those without. Using backwards logistic
regression to determine factors associated with VDD, the multivariate analysis used all demographic
variables in table 1. The significant independent factors for VDD were BAME (OR 8·86, 95% CI 4.75–
16.52; p<0.001) and seroconversion (OR 2.15, 95% CI 1.11–4.17; p=0.023). The overall predictive power of
the model was 77.9% (95% CI 71.1–84.7, SE 3.5%; p<0.001) indicated by the area under the receiver
operator characteristic (ROC) curve.
Self-reported symptoms in healthcare workers (n=386), included fever (n=235, 61%), breathlessness
(n=186, 48%), cough (n=117, 30%), loss of smell/taste (n=169, 44%), body aches/pains (n=274, 71%),
fatigue (n=339, 88%), diarrhoea (n=115, 30%) and sore throat (n=197, 51%). VDD staff experienced more
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body aches/pains (82% versus 69%; p=0.045) but there were no significant differences in other symptoms
reported between groups.
Seroconversion was higher in healthcare workers with VDD compared to those without (n=44/61, 72%
versus n=170/331, 51%; p=0.003), representing an absolute increase of 13 cases in the VDD group.
Seroconversion was higher in BAME males with VDD compared to those without (n=17/18, 94% versus
n=12/23, 52%; p=0.005); no differences were observed in the other ethnic–gender sub-analysis. Using
backwards logistic regression to determine factors associated with seroconversion, the multivariate analysis
used all the variables from table 1; only VDD was a significant independent risk factor for developing
seroconversion (OR 2.6, 95% CI 1.41–4.80; p=0.002). The overall predictive power of the model was 55·5%
(95% CI 49.8–61.2, SE 2.9%; p=0.06) as indicated by the area under the ROC curve.
To our knowledge this is the first study to investigate VDD prevalence in a UK healthcare worker cohort.
VDD was relatively uncommon (15.6%) and lower than healthcare worker studies published in the USA
and Gulf Areas, which may in part reflect differences in reference ranges and vitamin D assays used [10].






Subjects n 392 61 331
Age years 41 (30–50) 35 (28–47.5) 42 (31–50) 0.073
Gender
Female 285 (73%) 40 (66%) 245 (74%) 0.112
Male 100 (26%) 21 (34%) 79 (24%)
Not stated 7 (2%) 7 (2%)
BMI kg·m−2 25.9 (22.9–30.1) 25.4 (22.9–30.8) 26.0 (22.9–30.1) 0.794
Ethnicity
White 279 (71%) 18 (30%) 261 (79%) <0.0001
BAME 108 (28%) 43 (70%) 65 (20%)
Not stated 5 (1%) 5 (2%)
Comorbidities
None 240 (61%) 40 (66%) 200 (60%) 0.478
One or more 152 (39%) 21 (34%) 131 (40%)
Job role
Junior doctor 50 (13%) 15 (25%) 35 (11%) 0.029#
Consultant 65 (17%) 7 (11%) 58 (18%)
Junior nurse 65 (17%) 12 (20%) 53 (16%)
Senior nurse 66 (17%) 7 (11%) 59 (18%)
Physiotherapist 28 (7%) 4 (7%) 24 (7%)
Laboratory worker 26 (7%) 7 (11%) 19 (6%)
Radiology/theatre staff/
pharmacy
21 (5%) 1 (2%) 20 (6%)
Secretary/administrator 35 (9%) 2 (3%) 33 (10%)
Healthcare assistant/
phlebotomist
36 (9%) 6 (10%) 30 (9%)
Seroconversion
Yes 214 (55%) 44 (72%) 170 (51%) 0.003
No 178 (45%) 17 (28%) 161 (49%)
Data are presented as median (interquartile range) or n (%), unless otherwise indicated. Vitamin D
deficient is Serum 25(OH)D3 <30 nmol·L
−1, while not deficient is ⩾30 nmol·L−1. Where proportions are
shown, they were calculated using the n numbers shown in columns as denominator; p-values were
calculated using Mann–Whitney test for data presented as median and interquartile range, and by Fisher’s
exact test for data presented as n (%), with p<0.05 considered significant. The sample size for the
backward logistic regression is 379, with 13 excluded from this analysis; seven because gender was not
stated, five due to ethnicity not stated and one with body mass index (BMI) unknown. Age and BMI were
treated as continuous variables, job role as nine categories, while all others were treated as dichotomous.
Eight participants were taking vitamin D supplements, one in the vitamin D deficient group and seven in
the non-vitamin D deficient group. Comorbidities were classified as shown because they were uncommon
in this cohort, with the most common comorbidities being hypertension (n=34, 9%) and asthma (n=26, 7%).
#: p-value of 0.226 when excluding junior doctor group in analysis. BAME: Black, Asian and minority ethnic
demographic group.
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The increase in VDD seen in junior doctors echoes previous findings of junior doctors have lower levels
than senior doctors [10], which may be due to increased frontline work and different shift patterns.
Our data supports previous findings of higher VDD in BAME ethnicity [4]. While BAME was not an
independent risk factor for seroconversion, our sub-group analysis found that VDD BAME males may be
most at risk from COVID-19 as there was remarkably high seroconversion rate of 94% in this sub-group.
Although this is a cohort of mild COVID-19, being BAME and male are known risk factors for a severe
outcome from COVID-19.
Our study showing VDD as an independent risk factor for COVID-19 seroconversion is consistent with
others including a large US study which found that COVID-19 positivity was inversely related to patient
vitamin D levels in the preceding 12 months [11]. Additional data from Israel found low vitamin D
increased the risk of COVID-19 positivity and COVID-19 related hospitalisation [12]. Furthermore, a
recent open labelled clinical trial from Spain provided a proof of concept that high-dose vitamin D
treatment may be useful therapy for severe COVID-19 [13].
The role of vitamin D in modulating the immune response to COVID-19 is likely to be multifactorial.
Vitamin D increases the production of antimicrobial peptides in the respiratory epithelium, which may
protect against viral infection. Also, vitamin D supplementation has been shown to reduce viral upper
respiratory tract infections in metanalysis [14]. Vitamin D may help reduce the body’s response to
COVID-19; older patients with VDD (<30 nmol·L−1) had higher D-dimer levels, a marker of inflammation
and vascular damage, and required more noninvasive ventilation support [15]. There is a bidirectional
association between VDD and COVID-19 in our study and therefore it is unclear if VDD is a cause and/
or consequence of COVID-19.
This study has several limitations. Firstly, staff were recruited from a single NHS trust, although it is the
second largest in the UK, spanning four hospital sites. Secondly, as the healthcare workers had mild
COVID-19, this study does not inform of the role of VDD in severe COVID-19. Thirdly, due to relatively
small sample size, we were unable to analyse the differences between staff from different BAME
sub-groups. Fourthly, there is a risk of bias from recruiting individuals with self-reported symptoms
compared to a cross-sectional survey of all healthcare workers. Finally, other confounders such as
sociocultural factors which may affect risk of transmission and/or VDD were not addressed.
In summary, in healthcare workers who have isolated due to symptoms of COVID-19, those of BAME
ethnicity are at the highest risk of VDD. Furthermore, VDD was an independent risk factor for
development of COVID-19 seroconversion, with the biggest differences seen in the BAME male group.
Therefore, we suggest future high-dose vitamin D treatment trials should target such at risk groups within
healthcare workers with aim of potentially preventing or alleviating COVID-19.
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